Page last updated: 2024-11-04

fenbendazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Fenbendazole is a broad-spectrum antiparasitic drug used to treat various internal and external parasites in animals. It is a benzimidazole derivative that acts by interfering with microtubule formation in parasites, inhibiting their growth and reproduction. Fenbendazole is effective against roundworms, tapeworms, and some flukes. It is commonly used in livestock, companion animals, and aquaculture. Research into fenbendazole focuses on its efficacy against emerging parasitic threats, its potential for use in human medicine, and its environmental impact. The drug has been studied for its potential to treat certain types of cancer and its efficacy against parasitic infections in humans. However, further research is needed to understand its long-term effects and optimize its use.'

Fenbendazole: Antinematodal benzimidazole used in veterinary medicine. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

fenbendazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted at positons 2 and 5 by (methoxycarbonyl)amino and phenylsulfanediyl groups, respectively. A broad-spectrum anthelmintic, it is used, particularly in veterinary medicine, for the treatment of nematodal infections. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3334
CHEMBL ID37161
CHEBI ID77092
SCHEMBL ID166352
SCHEMBL ID8469702
SCHEMBL ID20796999
MeSH IDM0008324

Synonyms (202)

Synonym
methyl n-[5-(phenylsulfanyl)-1h-1,3-benzodiazol-2-yl]carbamate
AKOS005448335
AB00052199-14
AB00052199-13
BRD-K51318897-001-04-7
OPREA1_477843
MLS000069723 ,
DIVK1C_000257
KBIO1_000257
SPECTRUM_001254
phenbendasol
methyl 5-(phenylthio)-2-benzimidazolecarbamate
fenbendazol [inn-spanish]
einecs 256-145-7
fenbendazol
carbamic acid, (5-(phenylthio)-1h-benzimidazol-2-yl)-, methyl ester
panacur
fenbendazole [usan:ban:inn]
fenbendazolum [inn-latin]
2-(methoxycarbonylamino)-5-(phenylthio)benzimidazole
2-benzimidazolecarbamic acid, 5-(phenylthio)-, methyl ester
ccris 7309
methyl (5-(phenylthio)-1h-benzimidazol-2-yl)carbamate
hoe 881v
PRESTWICK_213
NCGC00016855-01
cas-43210-67-9
BPBIO1_000219
SPECTRUM5_001359
[5-(phenylthio)-1h-benzimidazol-2-yl]carbamic acid methyl ester
hoe-881v
fenbendazole
methyl n-(5-phenylsulfanyl-1h-benzimidazol-2-yl)carbamate
43210-67-9
fenbendazole (usp/inn)
PRESTWICK2_000210
panacur [veterinary] (tn)
D04140
BSPBIO_000199
AB00052199
NCGC00022515-03
NCGC00022515-04
smr000058217
KBIO3_001882
KBIO2_006870
KBIO2_001734
KBIOGR_001479
KBIOSS_001734
KBIO2_004302
SPBIO_002120
NINDS_000257
PRESTWICK1_000210
SPECTRUM3_000911
PRESTWICK0_000210
SPECTRUM4_001010
SPBIO_000139
SPECTRUM2_000040
SPECTRUM1501016
PRESTWICK3_000210
IDI1_000257
NCGC00016855-02
NCGC00022515-05
methyl [5-(phenylsulfanyl)-1h-benzimidazol-2-yl]carbamate
STK378581
fenbendazole, >=98%
HMS2090G12
HMS2092B11
nsc-757824
fenbendazole for veterinary use
chebi:77092 ,
hoe 881y
hoe-881y
CHEMBL37161 ,
panacur aquasol
HMS500M19
HMS1568J21
HMS1921D03
methyl n-(6-phenylsulfanyl-1h-benzimidazol-2-yl)carbamate
HMS2095J21
methyl [5-(phenylthio)benzimidazol-2-yl]carbamate
[5-(phenylthio)benzimidazol-2-yl]carbamic acid methyl ester
F0812
tox21_301828
NCGC00255694-01
dtxcid8020672
dtxsid0040672 ,
A826225
n-[6-(phenylthio)-1h-benzimidazol-2-yl]carbamic acid methyl ester
pharmakon1600-01501016
nsc757824
tox21_110649
HMS2234P14
CCG-39631
NCGC00016855-05
NCGC00016855-08
NCGC00016855-07
NCGC00016855-04
NCGC00016855-06
NCGC00016855-03
safe-guard
nsc 757824
unii-621bvt9m36
fenbendazole [usan:usp:inn:ban]
safe-quard
fenbendazolum
621bvt9m36 ,
FT-0630630
methyl [5-(phenylthio)-1h-benzimidazol-2-yl]carbamate
NCGC00016855-11
fenbendazole [who-dd]
oxfendazole for veterinary use impurity a [ep impurity]
fenbendazole [ema epar veterinary]
fenbendazole for veterinary use [ep monograph]
fenbendazole [usp monograph]
fenbendazole [usan]
fenbendazole for veterinary use [ep impurity]
fenbendazole [inn]
fenbendazole [green book]
fenbendazole [usp-rs]
oxfendazole impurity, fenbendazole- [usp impurity]
fenbendazole [mi]
S2468
5-(phenylthio)-2-benzimidazolecarbamic acid methyl ester
HMS3371J16
CCG-220210
HY-B0413
smr004701217
MLS006010049
SCHEMBL166352
NCGC00016855-10
tox21_110649_1
KS-5042
carbamic acid, n-[6-(phenylthio)-1h-benzimidazol-2-yl]-, methyl ester
SCHEMBL8469702
Q-201109
methyl 5-(phenylthio)-1h-benzo[d]imidazol-2-ylcarbamate
bdbm31047
cid_3334
(5-phenylsulfanyl-1h-benzoimidazol-2-yl)-carbamic acid methyl ester
HDDSHPAODJUKPD-UHFFFAOYSA-N
methyl 5-(phenylsulfanyl)-1h-benzimidazol-2-ylcarbamate #
carbamic acid, [5-(phenylthio)-1h-benzimidazol-2-yl]-, methyl ester
hoe 881
fenbendazole, pharmaceutical secondary standard; certified reference material
methyl (6-(phenylthio)-1h-benzo[d]imidazol-2-yl)carbamate
AKOS024462438
AB00052199_15
AB00052199_16
mfcd00144301
AC-8717
sr-01000000195
SR-01000000195-2
fenbendazole, vetranal(tm), analytical standard
fenbendazole, united states pharmacopeia (usp) reference standard
fenbendazole, european pharmacopoeia (ep) reference standard
HMS3656C04
sr-05000001768
SR-05000001768-1
SBI-0051634.P002
methyl 5-(phenyl-thio)-2-benzimidazole-carbamate
HMS3712J21
axilur
methyl 5-phenylthio-1h-benzimidazol-2-ylcarbamate
worm-a-rest
panacur (tn)
pancacur
SW196522-3
panacur; phenbendasol; safe-quard; hoe 881v; hoe881v; hoe-881v
BCP22258
fenbendazole (panacur)
DB11410
fenbendazole d3 (methyl d3)
C21876
Q908013
BRD-K56309460-001-03-0
BRD-K51318897-001-07-0
SCHEMBL20796999
methyl (5-(phenylthio)-1h-benzo[d]imidazol-2-yl)carbamate
SY052602
panacur 10% paste, safe-guard
panacur c canine
fenbendazole (usp monograph)
panacur suspension 10%
fenbendazol (inn-spanish)
panacur (veterinary)
fenbendazole (ema epar veterinary)
panacur, safe-guard
panacur granules 22.2%
fenbendazolum (inn-latin)
oxfendazole for veterinary use impurity a (ep impurity)
safe-guard type a medicated article
safe-guard aquasol
p02ca06
panacur c (otc), safe-guard canine (otc), panacur granules 22.2% (rx)
methyl (5-(phenylsulfanyl)-1h-benzimidazol-2-yl)carbamate
fenbendazole for veterinary use (ep impurity)
safe-guard, panacur
fenbendazole (usan:usp:inn:ban)
oxfendazole impurity, fenbendazole-(usp impurity)
fenbendazole for veterinary use (ep monograph)
fenbendazole (usp-rs)
(5-(phenylthio)-1h-benzimidazol-2-yl)carbamic acid methyl ester

Research Excerpts

Overview

Fenbendazole (FBZ) is a broad-spectrum benzimidazole commonly used in laboratory animal medicine as an anthelmintic for elimination of pinworms. It is not currently approved for game bird species in the United States.

ExcerptReferenceRelevance
"Fenbendazole is a broad-spectrum benzimidazole commonly used in laboratory animal medicine as an anthelmintic for elimination of pinworms. "( Effects of Maternal Fenbendazole on Litter Size, Survival Rate, and Weaning Weight in C57BL/6J Mice.
Hicks, KL; Lindstrom, KE; Roche, E; Wilkerson, JD, 2021
)
2.39
"Fenbendazole (FBZ) is a benzimidazole compound that is widely used as an anthelmintic agent and recent studies have expanded the scope of its pharmacological effects and application prospect."( Fenbendazole Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice via Suppression of Fibroblast-to-Myofibroblast Differentiation.
Ding, L; Guo, X; Pan, X; Rosas, I; Wan, R; Wang, L; Wang, N; Xu, K; Yang, J; Yu, G; Zhao, W, 2022
)
2.89
"Fenbendazole (FBZ) is a common antiparasitic treatment used in research rodent colonies for biosecurity purposes. "( Effects of fenbendazole on fecal microbiome in BPH/5 mice, a model of hypertension and obesity, a brief report.
Barras, ED; Beckers, KF; Childers, GW; Liu, CC; Schulz, CJ; Sones, JL; Stout, RW, 2023
)
2.74
"Fenbendazole is a highly effective benzimidazole-class anthelmintic in animals."( Safety of fenbendazole in common peafowl (Pavo cristatus).
Abbas, S; Ali, A; Aqil, K; Khan, MI; Nisa, Q; Qayyum, R; Shah, MA; Umar, S; Yaqoob, M; Yaseen, MA; Younus, M, 2018
)
1.6
"Fenbendazole, is an effective benzimidazole anthelmintic that prevents parasite infection in both human and veterinary health care. "( Fenbendazole induces apoptosis of porcine uterine luminal epithelial and trophoblast cells during early pregnancy.
Lim, W; Park, H; Song, G; You, S, 2019
)
3.4
"Fenbendazole is an anthelmintic drug widely used to treat and prevent pinworm infection in laboratory rodents. "( Effect of fenbendazole on an autoimmune mouse model.
Altman, NH; Cray, C; Watson, T; Zaias, J, 2013
)
2.23
"Fenbendazole is a highly effective benzimidazole-class anthelmintic that is not currently approved for game bird species in the United States."( Safety of fenbendazole in Chinese ring-necked pheasants (Phasianus colchicus).
Dzikamunhenga, R; Griffith, R; Hostetter, S; Larson, W; Laudenslager, T; Lillie, B; MacFarlane, W; Tell, LA; Vickroy, T; Wetzlich, S; Whitley, E; Yaeger, M, 2014
)
1.53
"Fenbendazole (FBZ) is an anthelmintic drug widely used to treat and prevent pinworm outbreaks in laboratory rodents. "( Effects of fenbendazole on routine immune response parameters of BALB/c mice.
Altman, NH; Cray, C; Villar, D; Zaias, J, 2008
)
2.18
"Fenbendazole is a benzimidazole anthelmintic that is widely used in veterinary medicine."( Ecotoxicological multilevel-evaluation of the effects of fenbendazole exposure to Chironomus riparius larvae.
Bang, HW; Kwak, IS; Park, J; Park, K, 2009
)
1.32
"Fenbendazole is a broad-spectrum anthelmintic drug widely used to prevent or treat nematode infections in laboratory rodent colonies. "( Exacerbation of acetaminophen hepatotoxicity by the anthelmentic drug fenbendazole.
Gardner, CR; Laskin, DL; Laskin, JD; Mishin, V, 2012
)
2.06
"Fenbendazole (FBZ) is an anthelmintic drug known to be a potent CYP1A2 inducer. "( Lack of modification of 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx)-induced hepatocarcinogenesis in rats by fenbendazole--a CYP1A2 inducer.
Asamoto, M; Hirose, M; Inaguma, S; Ogiso, T; Shirai, T; Suzuki, S; Takahashi, S, 2002
)
1.97
"Fenbendazole (FBZ) is a common, highly efficacious broad-spectrum anthelmintic drug used to treat and limit rodent pinworm infections. "( Prophylactic fenbendazole therapy does not affect the incidence and onset of type 1 diabetes in non-obese diabetic mice.
Franke, DD; Shirwan, H, 2006
)
2.15
"Fenbendazole is an anthelminthic that may be used in an extralabel manner for the treatment of intestinal parasitism in wildlife species. "( Presumptive fenbendazole toxicosis in North American porcupines.
Miller, MA; Neiffer, DL; Terrell, SP; Weber, MA, 2006
)
2.16
"Fenbendazole is a highly efficacious broad-spectrum anthelmintic with adulticidal, larvicidal, and ovicidal actions."( Practical and effective eradication of pinworms (Syphacia muris) in rats by use of fenbendazole.
Coghlan, LG; Lee, DR; Psencik, B; Weiss, D, 1993
)
1.23
"Fenbendazole is an effective and economical treatment for Giardia-associated diarrhea and growth rate reduction in calves."( Efficacy of fenbendazole for treatment of giardiasis in calves.
Cheng, KJ; Jelinski, M; McAllister, TA; Morck, DW; O'Handley, RM; Olson, ME; Royan, G, 1997
)
2.12
"Fenbendazole (FBZ) is an anthelmintic widely used in farm animals to treat parasitic infestations. "( Liquid chromatographic determination of fenbendazole residues in pig tissues after treatment with medicated feed.
Arboix, M; Capece, BP; Castells, E; Cristòfol, C; Pérez, B,
)
1.84
"Fenbendazole (FBZ) is a benzimidazole currently used for anthelmintic treatment of pinworm populations in numerous animal species although it is not currently approved for laboratory rodents in the U.S. "( The behavioral teratogenic potential of fenbendazole: a medication for pinworm infestation.
Barron, S; Baseheart, BJ; Deveraux, T; Segar, TM; Willford, JA,
)
1.84

Effects

Fenbendazole (FZ) has potential anti-cancer effects, but its poor water solubility limits its use for cancer therapy. It is associated with bone marrow hypoplasia and enteric damage in mammals and other species of birds.

ExcerptReferenceRelevance
"Fenbendazole (FZ) has potential anti-cancer effects, but its poor water solubility limits its use for cancer therapy. "( Anti-cancer effect of fenbendazole-incorporated PLGA nanoparticles in ovarian cancer.
Chang, CS; Cho, YJ; Choi, JJ; Choi, JK; Choi, JY; Han, HD; Hwang, JR; Lee, CM; Lee, JW; Noh, JJ; Ryu, JY; Won, JE, 2023
)
2.67
"Fenbendazole has been associated with bone marrow hypoplasia and enteric damage in mammals and other species of birds."( Bone marrow hypoplasia and intestinal crypt cell necrosis associated with fenbendazole administration in five painted storks.
Mangold, BJ; Miller, MA; Neiffer, DL; Terrell, SP; Weber, MA, 2002
)
1.27

Treatment

Fenbendazole reduced egg excretion by 45%, moxidectin by 91% and monepantel by 96%. Mice treated with the drug exhibited improved locomotor function, determined using the Basso mouse scale.

ExcerptReferenceRelevance
"Fenbendazole treatment reduced egg excretion by 45%, moxidectin by 91% and monepantel by 96%."( Current anthelmintic treatment is not always effective at controlling strongylid infections in German alpaca herds.
Hinney, B; Joachim, A; Kultscher, L; Schmäschke, R; Wittek, T, 2019
)
1.24
"The fenbendazole-treated mice exhibited improved locomotor function, determined using the Basso mouse scale, as well as improved tissue sparing following contusive SCI."( Fenbendazole improves pathological and functional recovery following traumatic spinal cord injury.
Crowdus, C; Geddes, JW; Kincer, J; Raza, K; Singh, R; Yu, CG, 2014
)
2.33
"Two fenbendazole treatment regimens (28 mg/kg per os q 12 hr for 21 days) and prednisone were required to eliminate the infection."( Paragonimosis in a cat and the temporal progression of pulmonary radiographic lesions following treatment.
Carey, H; Kruth, S; Nykamp, SG; Peregrine, AS,
)
0.61
"Fenbendazole treatment may be a useful option for farms struggling with persistent A."( Effect of fenbendazole in water on pigs infected with Ascaris suum in finishing pigs under field conditions.
Haimi-Hakala, M; Heinonen, M; Jukola, E; Lassen, B; Laurila, T; Oliviero, C; Orro, T, 2017
)
1.58
"Fenbendazole treatment effected the clinical recovery of the stocks within a few days and was very well tolerated."( Treatment of nematodiasis in poultry and game birds with fenbendazole.
Kirsch, R,
)
1.1
"fenbendazole treatment eliminated Giardia trophozoites from the small intestine of calves resulting in increased microvillus surface area and greater intestinal enzyme activity."( Giardiasis in dairy calves: effects of fenbendazole treatment on intestinal structure and function.
Buret, AG; Jelinski, M; McAllister, TA; O'Handley, RM; Olson, ME, 2001
)
1.3
"Fenbendazole treatment led to the inhibition of GDH, while G-6-PD, NADPH-D, cytochrome oxidase, monoamine oxidase and nonspecific esterase activity remained unaltered in the epithelium."( Histoenzymic effects of thiophenate and fenbendazole on the absorptive surfaces of Haemonchus contortus.
Kaur, M; Sood, ML, 1992
)
1.27
"Fenbendazole treatment resulted in little or no development of eggs and/or larvae in feces deposited 12 and 24 h after treatment, whereas development proceeded normally (compared with the control group) in ivermectin treated feces."( Effect of fenbendazole and ivermectin on development of strongylate nematode eggs and larvae in calf feces.
Miller, JE; Morrison, DG, 1992
)
1.41
"Fenbendazole treatment had no adverse effect on weight gain or feed intake."( Dose-titration to confirm the level of fenbendazole for control of Raillietina cesticillus in broiler chickens.
Couvillion, CE; Hackathorn, JH; Johnson, LK; Keirs, RW; Pote, LM; Schwartz, RD; Taylor, RF,
)
1.12
"Fenbendazole treatment resulted in greater (P less than .07) average daily gain than PT treatment in pigs penned outside."( Effect of fenbendazole and pyrantel tartrate on the induction of protective immunity in pigs naturally or experimentally infected with Ascaris suum.
Bessette, ME; Bodak-Koszalka, E; Hoyt, PG; Leon, DL; Southern, LL; Stewart, TB, 1989
)
1.4
"Treatment with fenbendazole at 100 mg/kg orally twice a day, for 1-3 months has been reported as being effective."( Successful treatment of pleural and peritoneal larval mesocestoidosis with fenbendazole in two dogs.
Genchi, M; Kramer, L; Venco, L; Vismarra, A, 2021
)
1.19
"Treatment with fenbendazole at a dose of 10mg/kg for 3 consecutive days, successfully cleared the infection."( Severe weight loss in lambs infected with Giardia duodenalis assemblage B.
Aloisio, F; Antenucci, P; Cacciò, SM; Filippini, G; Lepri, E; Pezzotti, G; Pozio, E, 2006
)
0.67
"Treatment with fenbendazole significantly reduced the abundance of transmission-stage excretion for all parasites, and reduced the prevalence in the case of Eimeria sp."( Changes in parasite transmission stage excretion after pheasant release.
Acevedo, P; Gortázar, C; Höfle, U; Rodríguez, O; Villanúa, D, 2006
)
0.67
"Pre-treatment with fenbendazole significantly reduced the nematode fecal egg count and significantly increased lamb body weight compared to the parasitized group."( Patterns of doramectin tissue residue depletion in parasitized vs nonparasitized lambs.
Cabezas, I; Nuñez, MJ; Palma, C; Pérez, R, 2008
)
0.66
"Treatment with fenbendazole and prednisolone resulted in a complete resolution of the clinical signs in two months time."( Angiostrongylus vasorum causing meningitis and detection of parasite larvae in the cerebrospinal fluid of a pug dog.
Cherubini, GB; Negrin, A; Steeves, E, 2008
)
0.69
"Treatment with fenbendazole at the recommended dose of groups of lambs infected with either strains showed no reduction in the DASP strain and a 70.5% reduction in the MKATA strain."( Resistance to benzimidazoles in Haemonchus contortus of sheep in Tanzania.
Bjørn, H; Kassuku, AA; Monrad, J; Nansen, P, 1990
)
0.62
"Treatment with fenbendazole decreased the number of specific sensitized lymphocytes, but favorably increased the resistance of pigs to reinfection."( Ascaris suum infection in pigs sensitizes lymphocytes but suppresses their responsiveness to phytomitogens.
Barta, O; Huang, LJ; Shaffer, LM; Simmons, LA; Stewart, TB, 1986
)
0.61

Toxicity

Fenbendazole (Panacur: Hoechst) has a low degree of toxicity, teratogenicity and adverse effects on the reproductive tract. administered to healthy cats at a dosage 5 times the dosage and 3 times the duration approved for use in dogs and wild felids did not cause any acute or subacute adverse reactions.

ExcerptReferenceRelevance
"Fenbendazole (Panacur: Hoechst) has a low degree of toxicity, teratogenicity and adverse effects on the reproductive tract, and a high degree of safety in experimental animals."( Safety of fenbendazole use in cattle.
Muser, RK; Paul, JW, 1984
)
2.11
" Chemical analysis, urinalysis, and hematologic, gross and microscopic pathologic, and bone marrow cytologic examinations revealed no significant adverse effect due to this drug."( Safety evaluation of fenbendazole in swine.
Booze, TF; Oehme, FW, 1983
)
0.58
" A fecal examination, coagulation tests, serum biochemical analyses, CBC, and urinalyses were performed before and 5, 9, and 21 days after initiation of treatment; cats were closely monitored for adverse reactions."( Evaluation of the safety of fenbendazole in cats.
Baggs, RB; Clark, T; Donoghue, AR; Partington, C; Schwartz, RD, 2000
)
0.6
"None of the cats developed any adverse reactions."( Evaluation of the safety of fenbendazole in cats.
Baggs, RB; Clark, T; Donoghue, AR; Partington, C; Schwartz, RD, 2000
)
0.6
"Fenbendazole administered to healthy cats at a dosage 5 times the dosage and 3 times the duration approved for use in dogs and wild felids did not cause any acute or subacute adverse reactions or pathologic changes."( Evaluation of the safety of fenbendazole in cats.
Baggs, RB; Clark, T; Donoghue, AR; Partington, C; Schwartz, RD, 2000
)
2.04
" To evaluate the potential toxicity of prophylactic anti- parasitic treatments on strains of mice that are commonly used as experimental models and in genetic engineering in our facility, we surveyed a number of strains and ages of mice for toxic reactions during treatment regimens that combine anthelminthic and anti-acaricidal agents."( Toxicity evaluation of prophylactic treatments for mites and pinworms in mice.
Frazier, S; Oberbeck, C; Rehg, JE; Straign, CM; Toth, LA, 2000
)
0.31
" No serious adverse effects to treatment were recorded: most of the minor adverse effects were gastrointestinal such as diarrhea (nine dogs), vomitus (eight dogs) and salivation (three dogs)."( Efficacy and safety of imidacloprid/moxidectin spot-on solution and fenbendazole in the treatment of dogs naturally infected with Angiostrongylus vasorum (Baillet, 1866).
Heine, J; Jensen, AL; Koch, J; Kristensen, AT; Willesen, JL, 2007
)
0.58
" No treated animals showed adverse events."( Efficacy and safety of imidacloprid 10%/moxidectin 1% spot-on formulation in the treatment of feline aelurostrongylosis.
Di Cesare, A; Heine, J; Iorio, R; Lohr, B; Milillo, P; Pampurini, F; Paoletti, B; Schaper, R; Traversa, D, 2009
)
0.35
" No treated animals showed adverse events."( Efficacy and safety of emodepside 2.1%/praziquantel 8.6% spot-on formulation in the treatment of feline aelurostrongylosis.
Bartolini, R; Di Cesare, A; Heine, J; Iorio, R; Lohr, B; Milillo, P; Pampurini, F; Schaper, R; Traversa, D, 2009
)
0.35
" Safe havens have intrinsic value for reefs through services such as environmental buffering, maintaining near-pristine reef conditions, or housing corals naturally adapted to future environmental conditions."( Contingency planning for coral reefs in the Anthropocene; The potential of reef safe havens.
Camp, EF, 2022
)
0.72

Pharmacokinetics

Study enriches the pharmacokinetic data of compound fenbendazole tablets using dogs as a model system.

ExcerptReferenceRelevance
" It did increase the tmax to 16."( Pharmacokinetics of fenbendazole in dogs.
Galbraith, EA; Harrison, P; Inglis, H; McKellar, QA, 1990
)
0.6
" A pharmacokinetic dose titration study was carried out in sheep with fenbendazole (5 mg kg-1) and piperonyl butoxide administered orally at 0, 15, 31, 63, 125 and 250 mg kg-1."( Interaction between fenbendazole and piperonyl butoxide: pharmacokinetic and pharmacodynamic implications.
Benchaoui, HA; McKellar, QA, 1996
)
0.85
"Oxfendazole, fenbendazole and albendazole were each administered at 5mgkg(-1) to sheep fitted with abomasal cannulae as a single bolus intra-ruminally or infused intra-abomasally at a declining exponential rate, with half-life equivalent to the rate of rumen fluid outflow."( Influence of ruminal bypass on the pharmacokinetics and efficacy of benzimidazole anthelmintics in sheep.
Hennessy, DR; Steel, JW, 1999
)
0.67
" The veterinary utility of 1a was shown by a pharmacodynamic and pharmacokinetic study performed in swine."( Highly water-soluble prodrugs of anthelmintic benzimidazole carbamates: synthesis, pharmacodynamics, and pharmacokinetics.
Berger, M; Chassaing, C; Heckeroth, A; Ilg, T; Jaeger, M; Kern, C; Schmid, K; Uphoff, M, 2008
)
0.35
" Within-drug and metabolite analysis of pharmacokinetic parameters included fixed effects of drug administration date, sex and breed of sire."( The effect of breed and sex on sulfamethazine, enrofloxacin, fenbendazole and flunixin meglumine pharmacokinetic parameters in swine.
Ashwell, MS; Baynes, RE; Bellis, B; Brooks, JD; Howard, JT; Maltecca, C; O'Nan, AT; Routh, P; Yeatts, JL, 2014
)
0.64
" This study enriches the pharmacokinetic data of compound fenbendazole tablets using dogs as a model system."( Development and analytical characterization of a new antiparasitic fenbendazole compound tablet and pharmacokinetic investigations after its oral administration to dogs.
Dai, C; Guo, H; Hao, Z; Li, Y; Qu, S; Wang, C; Zhang, R; Zhao, L; Zhu, J, 2018
)
0.96
" To quantitatively capture the relation between oxfendazole dose and exposure, a population pharmacokinetic model for oxfendazole and its metabolites, oxfendazole sulfone and fenbendazole, in humans was developed using a nonlinear mixed-effect modeling approach."( Population Pharmacokinetic Model of Oxfendazole and Metabolites in Healthy Adults following Single Ascending Doses.
An, G; Bach, T; Deye, G; Murry, DJ; Stebounova, LV; Winokur, P, 2021
)
0.81
" In this study, we compared the performance of FOCE, FOCE FAST, and two EM methods, namely importance sampling (IMP) and stochastic approximation expectation-maximization (SAEM), utilizing the rich pharmacokinetic data of oxfendazole and its two metabolites obtained from the first-in-human single ascending dose study in healthy adults."( Comparing the performance of first-order conditional estimation (FOCE) and different expectation-maximization (EM) methods in NONMEM: real data experience with complex nonlinear parent-metabolite pharmacokinetic model.
An, G; Bach, T, 2021
)
0.62
" The aim of our research was to study the pharmacokinetic profile and tissue residue depletion of fenbendazole (FBZ) and its metabolites: sulfoxide and sulfone in sheep after SFBZ treatment by high-performance liquid chromatography with tandem mass spectrometric detection and to evaluate its efficacy against gastrointestinal strongylatosis of sheep in field trials."( Pharmacokinetic profile, tissue residue depletion and anthelmintic efficacy of supramolecular fenbendazole.
Abramov, VE; Arisov, MV; Arkhipov, IA; Khalikov, SS; Kotchetkov, PP; Varlamova, AI, 2021
)
1.06

Compound-Compound Interactions

Fenbendazole should be used with caution during tumor studies because it may interact with other treatments and confound research results. The first study indicated that treatment of all animals with fenbENDazole at 15 mg/kg during 3 consecutive days combined with environmental measures resulted in a total reduction in cyst excretion for at least 2 weeks.

ExcerptReferenceRelevance
"Seven critical tests in equids were conducted with single doses of fenbendazole (5 mg kg-1) alone (Panacur--American Hoechst, Somerville, NJ); (2 tests with paste and 1 with suspension formulation) or in combination with piperazine (American Hoechst); (40 mg base kg-1); (4 tests with paste formulation)."( Critical tests in equids with fenbendazole alone or combined with piperazine: particular reference to activity on benzimidazole-resistant small strongyles.
Drudge, JH; Lyons, ET; Tolliver, SC, 1983
)
0.79
" The first study indicated that treatment of all animals with fenbendazole at 15 mg/kg during 3 consecutive days combined with environmental measures on the final day of treatment, which were either removal of bedding, thorough cleaning and ammonia 10% disinfection or relocation of the treated animals to a Giardia free environment, resulted in a total reduction in cyst excretion for at least 2 weeks."( Field testing of a fenbendazole treatment combined with hygienic and management measures against a natural Giardia infection in calves.
Claerebout, E; Geurden, T; Vercruysse, J, 2006
)
0.9
" Fenbendazole should be used with caution during tumor studies because it may interact with other treatments and confound research results."( Unexpected antitumorigenic effect of fenbendazole when combined with supplementary vitamins.
Dang, CV; Gao, P; Watson, J, 2008
)
1.53

Bioavailability

The influence of the host's physiology on the reduced bioavailability of fenbendazole is discussed. Pretreatment of goats with the inhibitor caused a greater than three-fold increase in the relative bioavailability.

ExcerptReferenceRelevance
"Differences in bioavailability of many drugs from their various dosage forms have been shown to be relatively common in human medicine."( Bioavailability and bioinequivalence of drug formulations in small animals.
Watson, AD, 1992
)
0.28
" The influence of the host's physiology on the reduced bioavailability of fenbendazole is discussed."( Influence of subclinical nematodosis on the kinetic disposition of fenbendazole in buffaloes.
Mathur, AC; Sanyal, PK; Sarkar, S, 1995
)
0.76
" The concentration of the drug in blocks and its bioavailability were measured using plasma oxfendazole as marker."( The uptake of fenbendazole by cattle and buffalo following long-term low-level administration in urea-molasses blocks.
Sanyal, PK; Singh, DK, 1993
)
0.65
" Administration of fenbendazole at a dose rate of 20 mg/kg in food, irrespective of fat content, did however significantly increase its bioavailability when compared to administration of the same dose as a bolus on an empty stomach."( Oral absorption and bioavailability of fenbendazole in the dog and the effect of concurrent ingestion of food.
Baxter, P; Galbraith, EA; McKellar, QA, 1993
)
0.88
" Pretreatment of goats with the inhibitor caused a greater than three-fold increase in the relative bioavailability of fenbendazole and fenbendazole sulphoxide."( Interaction between fenbendazole and piperonyl butoxide: pharmacokinetic and pharmacodynamic implications.
Benchaoui, HA; McKellar, QA, 1996
)
0.83
"In the present study the bioavailability of febantel paste and febantel suspension was investigated in the fully hydrated and the dehydrated camel."( The bioavailability of febantel in dehydrated camels.
Ben-Zvi, Z; Gussarsky, E; van Creveld, C; Yagil, R, 1996
)
0.29
" Bioavailability of fenbendazole was 27."( Pharmacokinetics of fenbendazole following intravenous and oral administration to pigs.
Friis, C; Petersen, MB, 2000
)
0.95
" The drug was rapidly absorbed after oral administration, but systemic bioavailability was low."( Pharmacokinetics of fenbendazole following intravenous and oral administration to pigs.
Friis, C; Petersen, MB, 2000
)
0.63
" However, the bioavailability of these drugs for tissues is very low due to their extremely low solubility, resulting in the administration of relatively high doses over a long period."( Treatment of Toxocara canis infections in mice with liposome-incorporated benzimidazole carbamates and immunomodulator glucan.
Hrckova, G; Velebný, S, 2001
)
0.31
" A higher metabolic capacity, first-pass effects and lower absorption of benzimidazoles in donkeys decrease bioavailability and efficacy compared to ruminants."( Plasma disposition and faecal excretion of oxfendazole, fenbendazole and albendazole following oral administration to donkeys.
Akar, F; Gokbulut, C; McKellar, QA, 2006
)
0.58
"Cell membrane permeability is an important determinant for oral absorption and bioavailability of a drug molecule."( Highly predictive and interpretable models for PAMPA permeability.
Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR, 2017
)
0.46
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Our final model incorporated mechanistic characterization of dose-limited bioavailability as well as different oxfendazole metabolic processes and provided insight into the significance of presystemic metabolism in oxfendazole and metabolite disposition."( Population Pharmacokinetic Model of Oxfendazole and Metabolites in Healthy Adults following Single Ascending Doses.
An, G; Bach, T; Deye, G; Murry, DJ; Stebounova, LV; Winokur, P, 2021
)
0.62
"The pharmacokinetics and bioavailability of fenbendazole and levamisole were determined in Caspian turtles after a single intravenous (i."( Pharmacokinetics and therapeutic efficacies of fenbendazole in comparison with levamisole in helminth-infected Caspian turtles (Mauremys caspica).
Abouhosseini Tabari, M; Giorgi, M; Khabbazian, FG; Navidi, N; Yazdani Rostam, MM; Youssefi, MR, 2023
)
1.43

Dosage Studied

Fenbendazole removed 100% of the worms if given as an oral suspension. Resorantel at a dosage rate of 130 mg kg-1 live body mass was found to be highly effective against Houttuynia struthionis in ostriches.

ExcerptRelevanceReference
" At a dosage of 5 mg/kg of body weight, fenbendazole removed 100% of the worms if given as an oral suspension, and 99."( Efficacy of fenbendazole against adult Dictyocaulus viviparus in experimentally infected calves.
Rubin, R; Saad, MB, 1977
)
0.9
"Fenbedazole, dosed to artificially infested cattle at 7,5 mg/kg live mass, was more than 80% effective in more than 80% of the treated animals against immature and adult Haemonchus placei, Ostertagia ostertagi; Cooperia spp."( The efficacy of fenbendazole at a dosage rate of 7,5 mg/kg against nematode infestations in cattle.
Malan, FS, 1979
)
0.61
"Sixteen sheep which had previously been infected with Ostertagia circumcincta were dosed with 4000 Trichostrongylus colubriformis larvae/day for four weeks, then given anthelmintic and killed at intervals thereafter."( The rate of recovery of intestinal morphology following anthelmintic treatment of parasitised sheep.
Angus, KW; Coop, RL; Sykes, AR, 1979
)
0.26
" The passage of Paragonimus eggs in the feces ceased after 3 days at the high dosage and after 3 to 8 days at the low dosage."( Fenbendazole for treatment of Paragonimus kellicotti infection in dogs.
Dubey, JP; Miller, TB; Sharma, SP, 1979
)
1.7
" Eight pups were treated with fenbendazole oral suspension (10%) at a dosage of 50 mg/kg of body weight/day for 3 days."( Use of fenbendazole suspension (10%) against experimental infections of Toxocara canis and Ancylostoma caninum in beagle pups.
Burke, TM; Roberson, EL, 1979
)
1
" A further 5 donkeys were dosed with a medicated lick (1 mg FBZ/g lick) until the oral consumption was 10 mg/kg body mass."( Anthelmintic efficiency of fenbendazole in equines.
Malan, FS; Reinecke, RK, 1979
)
0.56
" Pigs subjected to the same multiple egg dosing regimen but given feed containing fenbendazole immediately before, during and for 10 days after multiple dosing developed significantly more adult intestinal worms after challenge than any other group."( Patent infections of Ascaris suum in pigs: effect of previous exposure to multiple, high doses of eggs and various treatment regimes.
Froe, DL; Jonas, W; Stankiewicz, M, 1992
)
0.51
"Differences in bioavailability of many drugs from their various dosage forms have been shown to be relatively common in human medicine."( Bioavailability and bioinequivalence of drug formulations in small animals.
Watson, AD, 1992
)
0.28
"Groups of parasite-free lambs and calves which were either housed and fed hay and concentrates or were grazing on pasture were dosed separately with the oral anthelmintics fenbendazole and ivermectin (lambs only)."( Effects of diet on plasma concentrations of oral anthelmintics for cattle and sheep.
Blanchflower, WJ; Green, WP; Kennedy, DG; Mallon, TR; Taylor, SM, 1992
)
0.48
" If a properly dosed and administered drug failed to reduce herd mean pretreatment fecal egg count by 80%, it was considered ineffective in that flock, and the presence of parasites resistant to that drug was inferred."( Survey for drug-resistant gastrointestinal nematodes in 13 commercial sheep flocks.
Fleming, S; Moncol, D; Uhlinger, C, 1992
)
0.28
" The results indicate that fenbendazole does not alter the activity of hepatic microsomal monooxygenase system significantly in rats, mice and chickens at a dosage level of 10 mg/kg body weight."( Lack of in vitro and in vitro effects of fenbendazole on phase I and phase II biotransformation enzymes in rats, mice and chickens.
Dalvi, PS; Dalvi, RR; Gawai, KR, 1991
)
0.84
" Group-1 calves were treated with ivermectin (200 micrograms/kg of body weight, SC) at approximately 6-week intervals for a total of 8 treatments; group-2 calves were given the same dosage of ivermectin by the same route of administration as group-1 calves in November, March, and July; group-3 calves were given fenbendazole paste (5 mg/kg, PO) at the same times as group-2 calves; and group-4 calves served as untreated controls with provision for ivermectin salvage treatment."( Effects of ivermectin and fenbendazole in strategic treatment of gastrointestinal nematode infections in cattle.
Barras, SA; Hawkins, JA; Knox, JW; Williams, JC, 1990
)
0.75
"The efficacy, safety, and compatibility of fenbendazole (FBZ) and clorsulon (CLN) were tested after oral administration of label recommended and of higher (5x) dosage rates to calves naturally infected with gastrointestinal nematodes and Fasciola hepatica."( Efficacy of concomitant early summer treatment with fenbendazole and clorsulon against Fasciola hepatica and gastrointestinal nematodes in calves in Louisiana.
Fagan, N; Jacocks, M; Jones, E; Lutz, M; Malone, JB; Marbury, K; Williams, JC; Willis, E, 1990
)
0.79
" At that time, four groups of cows received a dose of fenbendazole (5 mg kg-1) with their calves receiving fenbendazole at the same dosage 28 days later."( Effect of a single strategically timed dose of fenbendazole on cow and calf performance.
Ciordia, H; McCampbell, HC; Myers, GH; Stuedemann, JA, 1989
)
0.78
"Resorantel at a dosage rate of 130 mg kg-1 live body mass was found to be highly effective against Houttuynia struthionis in ostriches when dosed alone or in combination with fenbendazole or levamisole."( The anthelmintic efficacy of resorantel against Houttuynia struthionis in ostriches.
Ashburner, AJ; du Plessis, C; Gruss, B; Malan, FS; Roper, NA, 1988
)
0.47
"5 vs 5 heifers/ha), and treatment [control vs dosing with a 10% suspension of fenbendazole (5 mg/kg of body weight) given orally 21 and 49 days after heifers were placed on pasture]."( Effect of stocking rate, grazing system, and fenbendazole treatment on subclinical parasitism in dairy heifers.
Kunkel, JR; Murphy, WM, 1988
)
0.76
"Two controlled tests (experiments D and E) were done to evaluate a fenbendazole (FBZ) paste dosage regimen (10 mg/kg once a day for 5 days) for activity against naturally occurring infections of migrating Strongylus vulgaris and S edentatus in the mesenteric arteries and ventral abdominal wall, respectively."( Fenbendazole in equids: further controlled tests with emphasis on activity of multiple doses against naturally occurring infections of migratory large strongyles.
Drudge, JH; Lyons, ET; Tolliver, SC, 1986
)
1.95
" When patency was established the sheep were divided into groups of six, and dosed orally with either TBZ (44 mg kg-1, 88 mg kg-1), fenbendazole (FBZ; 5 mg kg-1) or levamisole (7."( Anthelmintic evaluation of a thiabendazole-resistant strain of Ostertagia circumcincta recovered from sheep in England.
Britt, DP; Oakley, GA, 1986
)
0.48
"Fenbendazole at a dosage rate of 15 mg FBZ per kg body mass, was 99,7% effective against adult and 82,5% effective against 4th stage larvae (L4) of Libyostrongylus douglassi."( Anthelmintic efficacy of fenbendazole against Libyostrongylus douglassi and Houttuynia struthionis in ostriches.
Cooper, GG; Fockema, A; Malan, FS; Visser, E, 1985
)
2.02
" With all dosage groups considered, Strongyloides and Nematodirus eggs were most sensitive to treatment, with 100% reductions in fecal egg counts."( Efficacy of fenbendazole for endoparasite control in large herds of nondomestic ruminants.
Janssen, DL, 1985
)
0.65
"Fenbendazole, dosed to artificially infested cattle at 5 mg/kg live mass, was more than 60% effective in more than 60% of the treated animals against 1-7 day-old Dictyocaulus viviparus larvae reducing the worm load by 87%."( The efficacy of fenbendazole at a dosage rate of 5 mg/kg against Dictyocaulus viviparus.
Malan, FS; Roper, NA; Shabangu, G, 1983
)
2.05
"Fenbendazole, dosed to experimentally infested sheep at 5 mg/kg live mass, against immature Dictyocaulus filaria, was more than 80% effective in more than 80% of the animals."( The efficacy of fenbendazole at a dosage rate of 5 mg/kg against the third and fourth stage larvae of Dictyocaulus filaria in sheep.
Malan, FS; Roper, NA, 1983
)
2.05
"After twenty weeks of continuous dosing with Trichostrongylus colubriformis larvae substantial, but declining, numbers of worms had persisted in most of the lambs examined, although there were wide inter-individual variations."( Intestinal enzyme activity in lambs chronically infected with Trichostrongylus colubriformis: effect of anthelmintic treatment.
Jones, DG, 1983
)
0.27
" Approximately 8 weeks later, 4 of the foals were given fenbendazole (10% suspension) at a dosage rate of 10 mg/kg of body weight daily for 5 days and 4 foals were given the suspension at a dosage rate of 50 mg/kg daily for 3 days; the remaining foals were given a placebo."( Effectiveness of fenbendazole against later 4th-stage Strongylus vulgaris in ponies.
Baird, JD; McCraw, BM; Pennock, PW; Slocombe, JO, 1983
)
0.85
" colubriformis for 10 weeks, dosed with fenbendazole and given no further larvae."( Chronic infections with Trichostrongylus colubriformis in lambs: influence of anthelmintic treatment on intestinal morphology and mucosal cell populations.
Angus, KW; Coop, RL, 1984
)
0.54
"Fenbendazole was given in the feed to swine at a cumulative dosage of 9 mg/kg of body weight over a period of 3, 6, and 12 days to compare efficacy."( Evaluation of fenbendazole as an extended anthelmintic treatment regimen for swine.
Corwin, RM; Muser, RK; Pratt, SE, 1984
)
2.07
"Forty-five commercial-grade Angus calves naturally infected with tapeworms (Moniezia sp) were used in 2 controlled experiments to evaluate the cestocidal efficacy of 3 dosage levels of fenbendazole, methyl-5-(phenylthio) -2-benzimidazolecarbamate."( Efficacy of fenbendazole against tapeworms in calves.
Ciordia, H; McCampbell, HC; Stuedemann, JA, 1983
)
0.84
" In dosage titration and confirmational studies, using worm counts in naturally infected dogs, the drug was 98%-100% effective at a dosage of 50 mg/kg of body weight/day for 3 days against the commonly occurring nematodes of dogs (ascarids, hookworms, and whipworms) and against Taenia tapeworms."( Evaluation of granulated fenbendazole as a treatment for helminth infections in dogs.
Burke, TM; Roberson, EL, 1982
)
0.57
" A further 5 donkeys were dosed with a medicated lick (1 mg FBZ/g lick) until the oral consumption was 10mg/kg body mass."( Anthelmintic efficiency of fenbendazole in equines.
Malan, FS; Reinecke, RK, 1980
)
0.56
"Fenbendazole, at low dosage levels, was evaluated for its efficacy against inhibited early fourth stage larvae of Ostertagia ostertagi in naturally infected, yearling beef cattle in April."( Further studies on the efficacy of fenbendazole against inhibited larvae of Ostertagia ostertagi.
Baumann, BA; Hoerner, TJ; Knox, JW; Snider, TG; Williams, JC, 1981
)
1.98
"The anthelmintic efficacy of fenbendazole, dosed to artificially infested cattle at 5 mg/kg live mass was determined against immature and adult Haemonchus placei."( The efficacy of fenbendazole at a dosage rate of 5 mg/kg against nematode infestations in cattle.
Malan, FS, 1981
)
0.9
" The drug was administered in 20 g of canned food on each of 3 days at a dosage of 50 mg/kg of body weight/day."( Evaluation of granulated fenbendazole (22.2%) against induced and naturally occurring helminth infections in cats.
Burke, TM; Roberson, EL, 1980
)
0.56
"The anthelmintic efficacy of fenbendazole FBZ against Moniezia expansa was tested in sheep and cattle at a dosage rate of 10 mg FBZ per kg body mass."( Anthelmintic efficacy of fenbendazole against cestodes in sheep and cattle.
Malan, FS, 1980
)
0.86
" Both anthelmintics were dosed at 5 mg/kg."( A re-assessment of the efficacy of febantel (Rintal) and fenbendazole (Panacur) against Strongyloides papillosus in sheep and goats.
Grimbeek, P; Terblanche, HJ, 1980
)
0.51
" canis eggs shed into the environment, but that multiple dosing remains essential for this purpose."( Studies on the control of Toxocara canis in breeding kennels.
Dick, IG; Fisher, MA; Hutchinson, MJ; Jacobs, DE, 1994
)
0.29
" These results indicate that the current label dosage (for the treatment of Toxocara canis, Toxascaris leonina, Ancylostoma caninum, Uncinaria stenocephala, Trichuris vulpis, and Taenia pisiformis, but not Giardia spp) of fenbendazole (50 mg/kg, PO, q 24 h, for 3 doses) is also effective for treating giardiasis in dogs."( Efficacy of fenbendazole against giardiasis in dogs.
Barr, SC; Bowman, DD; Heller, RL, 1994
)
0.85
" The assay has been used for statutory testing purposes and for measuring the levels of fenbendazole and oxfendazole in liver and muscle from sheep after dosing with a commercial anthelmintic containing fenbendazole."( Determination of fenbendazole and oxfendazole in liver and muscle using liquid chromatography-mass spectrometry.
Blanchflower, WJ; Cannavan, A; Kennedy, DG, 1994
)
0.85
" The exposure to febantel and its metabolites in fully hydrated camels was significantly higher in camels dosed with febantel paste compared to febantel suspension, as measured by AUC and Cmax."( The bioavailability of febantel in dehydrated camels.
Ben-Zvi, Z; Gussarsky, E; van Creveld, C; Yagil, R, 1996
)
0.29
" A combination of food withdrawal and divided dosing did not further increase treatment efficacy in goats."( Comparative field evaluation of divided-dosing and reduced feed intake upon treatment efficacy against resistant isolates of Teladorsagia circumcincta in sheep and goats.
Barrett, M; Jackson, E; Jackson, F; McKellar, QA; Patterson, M,
)
0.13
" Group 1 served as untreated controls, and groups 2, 3 and 4 were dosed with a levamisole SRD, a fenbendazole SRD, and an ivermectin SRD, respectively."( Effect of three sustained-release devices on parasitic bronchitis in first year calves.
Ascher, F; Borgsteede, FH; Cornelissen, JB; Gaasenbeek, CP; van der Linden, JN, 1998
)
0.52
"1 mg kg-1) to Merino sheep, the AUC0-infinity of albendazole sulphoxide at the lower dosage of netobimin, was significantly increased (75."( Bioavailability of albendazole sulphoxide after netobimin administration in sheep: effects of fenbendazole coadministration.
Alvarez, AI; Garcia, JL; Larrodé, OM; Merino, G; Prieto, JG; Redondo, PA, 1999
)
0.52
" Cats in the treatment groups were given fenbendazole at a dosage of 50, 150, or 250 mg/kg, PO, every 24 hours for 9 days; control cats were given a placebo."( Evaluation of the safety of fenbendazole in cats.
Baggs, RB; Clark, T; Donoghue, AR; Partington, C; Schwartz, RD, 2000
)
0.87
"Fenbendazole administered to healthy cats at a dosage 5 times the dosage and 3 times the duration approved for use in dogs and wild felids did not cause any acute or subacute adverse reactions or pathologic changes."( Evaluation of the safety of fenbendazole in cats.
Baggs, RB; Clark, T; Donoghue, AR; Partington, C; Schwartz, RD, 2000
)
2.04
" Administration to rats, dosed with Nippostrongylus brasiliensis, of pyrantel and/or fenbendazole and pigs, dosed with Ascaris and Oesophagostomum, of dichlorvos (DDVP) loaded onto zeolite Y was more successful in killing adult worms than administration of the pure drug alone."( The use of zeolites as slow release anthelmintic carriers.
Dyer, A; Morgan, S; Wells, P; Williams, C, 2000
)
0.53
"Communally grazed sheep were dosed at 4-, 12-, 24- or 48-week intervals for 1 year."( The effect of strategic anthelmintic treatment on internal parasites in communally grazed sheep in a semi-arid area as reflected in the faecal nematode egg count.
Bakunzi, FR; Serumaga-Zake, PA, 2000
)
0.31
" The drug was administered to each treated bitch once daily in canned dog food at a dosage of 50 mg/kg body weight."( Fenbendazole treatment of pregnant bitches to reduce prenatal and lactogenic infections of Toxocara canis and Ancylostoma caninum in pups.
Burke, TM; Roberson, EL, 1983
)
1.71
" Milk was collected immediately before dosing and then every 12 h for 5 days."( Analysis of fenbendazole residues in bovine milk by ELISA.
Barker, SA; Bates, AH; Binder, RG; Brandon, DL; Montague, WC; Whitehand, LC, 2002
)
0.69
"2 mg/kg, the dosage registered for other host species."( Anthelmintic treatment in horses: the extra-label use of products and the danger of under-dosing.
Matthee, S, 2003
)
0.32
" Twenty-six of the horses previously dosed with pyrantel or fenbendazole, and which still excreted >/=150 eggs per gram of faeces 14 days after treatment, were dewormed with ivermectin and fenbendazole or pyrantel in order to eliminate the remaining cyathostomins."( A field study on the effect of some anthelmintics on cyathostomins of horses in sweden.
Höglund, J; Kuzmina, T; Lind, EO; Uggla, A; Waller, PJ, 2007
)
0.58
" In this 125-day study, six male Hermann's tortoises (Testudo hermanni) were treated orally with two 5-day courses of fenbendazole 2 wk apart at a dosage of 50 mg/kg."( Hematologic and plasma biochemical changes associated with fenbendazole administration in Hermann's tortoises (testudo hermanni).
Burks, K; Doherty, D; Lydick, D; Neiffer, DL, 2005
)
0.78
" The next year, an early-season treatment program with three administrations of fenbendazole at the same dosage at 3-wk intervals was used."( Evaluation of three strategic parasite control programs in captive wild ruminants.
Dorny, P; Goossens, E; Vercammen, F; Vercruysse, J, 2006
)
0.56
" However, only low concentrations of AlCl(3) induced a significant effect on both the zeta potential and stability of the drug, leading to a "free-layered" sedimentation and a very easy redispersion which could be of great interest in the design of an oral pharmaceutical dosage form for veterinary."( Stability of fenbendazole suspensions for veterinary use. Correlation between zeta potential and sedimentation.
Arias, JL; Clares, B; López-Viota, M; Ruiz, MA, 2008
)
0.72
" Treatment was randomly assigned to one of the two groups, and all animals in the treatment group received a daily oral dosage of 15mg fenbendazole per kg bodyweight during 3 consecutive days."( The effect of a fenbendazole treatment on cyst excretion and weight gain in calves experimentally infected with Giardia duodenalis.
Casaert, S; Claerebout, E; De Wilde, N; Geurden, T; Pohle, H; Vandenhoute, E; Vercruysse, J, 2010
)
0.91
" Fenbendazole did not alter the dose-response curves for radiation or docetaxel; instead, the agents produced additive cytotoxicities."( Fenbendazole as a potential anticancer drug.
Duan, Q; Liu, Y; Rockwell, S, 2013
)
2.74
" Further studies have to be performed to transform coacervates into a solid dosage form and to prove broad applicability to other poorly soluble drugs."( Formulation of poorly water-soluble drugs via coacervation--a pilot study using febantel.
Antunes da Fonseca, A; De Geest, BG; De Jaeghere, W; Remon, JP; Van Bocxlaer, J; Vervaet, C, 2013
)
0.39
" Risk factor analysis provided support to advocate for FEC-based treatment regimens combined with individual anthelmintic dosage and the enforcement of tighter biosecurity around horse introduction."( Risk factor analysis of equine strongyle resistance to anthelmintics.
Blanchard, A; Bois, I; Cortet, J; Couroucé, A; Dubès, C; Guégnard, F; Guillot, J; Guyot-Sionest, Q; Jacquiet, P; Landrin, V; Larrieu, C; Leblond, A; Majorel, G; Sallé, G; Wittreck, S; Woringer, E, 2017
)
0.46
" The treatment protocols were performed at 14 day-intervals between each dosage of PZQ."( Experimental avian philophthalmosis: Evaluation of diagnosis and treatment of chickens infected with Philophthalmus gralli (Trematoda: Philophthalmidae).
Assis, JCA; Martins, NRS; Pinto, HA, 2018
)
0.48
" The model can be used to predict oxfendazole disposition under new dosing regimens to support dose optimization in humans."( Population Pharmacokinetic Model of Oxfendazole and Metabolites in Healthy Adults following Single Ascending Doses.
An, G; Bach, T; Deye, G; Murry, DJ; Stebounova, LV; Winokur, P, 2021
)
0.62
" Here, we report the efficacy of fenbendazole at a lower dosage (50 mg/kg twice a day) in two dogs with pleural and peritoneal mesocestoidosis."( Successful treatment of pleural and peritoneal larval mesocestoidosis with fenbendazole in two dogs.
Genchi, M; Kramer, L; Venco, L; Vismarra, A, 2021
)
1.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
antinematodal drugA substance used in the treatment or control of nematode infestations.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
benzimidazolesAn organic heterocyclic compound containing a benzene ring fused to an imidazole ring.
carbamate esterAny ester of carbamic acid or its N-substituted derivatives.
aryl sulfideAny organic sulfide in which the sulfur is attached to at least one aromatic group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (60)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency5.01190.044717.8581100.0000AID485294
Chain A, CruzipainTrypanosoma cruziPotency39.81070.002014.677939.8107AID1476
LuciferasePhotinus pyralis (common eastern firefly)Potency2.21190.007215.758889.3584AID1224835; AID588342
glp-1 receptor, partialHomo sapiens (human)Potency1.12200.01846.806014.1254AID624417
RAR-related orphan receptor gammaMus musculus (house mouse)Potency30.21920.006038.004119,952.5996AID1159521; AID1159523
ATAD5 protein, partialHomo sapiens (human)Potency23.72460.004110.890331.5287AID504466; AID504467
Fumarate hydrataseHomo sapiens (human)Potency1.32070.00308.794948.0869AID1347053
PPM1D proteinHomo sapiens (human)Potency1.17090.00529.466132.9993AID1347411
TDP1 proteinHomo sapiens (human)Potency0.47480.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency2.46130.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency8.09410.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743036; AID743042; AID743053; AID743054; AID743063
Smad3Homo sapiens (human)Potency35.48130.00527.809829.0929AID588855
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency30.63790.013326.981070.7614AID1346978
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency5.34200.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency2.21810.000417.946075.1148AID1346795
EWS/FLI fusion proteinHomo sapiens (human)Potency1.45570.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency1.33610.000214.376460.0339AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency3.40950.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency3.51270.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency7.76120.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency4.28200.375827.485161.6524AID743217; AID743220
pregnane X nuclear receptorHomo sapiens (human)Potency7.48730.005428.02631,258.9301AID1346982; AID1346985
estrogen nuclear receptor alphaHomo sapiens (human)Potency12.03930.000229.305416,493.5996AID743069; AID743075; AID743079; AID743080; AID743091
polyproteinZika virusPotency1.32070.00308.794948.0869AID1347053
67.9K proteinVaccinia virusPotency0.89130.00018.4406100.0000AID720579; AID720580
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency1.49590.001024.504861.6448AID743215
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency13.48530.023723.228263.5986AID743223
caspase-3Homo sapiens (human)Potency30.63790.013326.981070.7614AID1346978
IDH1Homo sapiens (human)Potency1.15820.005210.865235.4813AID686970
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency1.99530.035520.977089.1251AID504332
aryl hydrocarbon receptorHomo sapiens (human)Potency4.92350.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency1.27450.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency24.33650.001628.015177.1139AID1224843
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency2.68610.057821.109761.2679AID1159526; AID1159528
nuclear receptor subfamily 1, group I, member 2Rattus norvegicus (Norway rat)Potency1.25890.10009.191631.6228AID1346983
Histone H2A.xCricetulus griseus (Chinese hamster)Potency58.14890.039147.5451146.8240AID1224845; AID1224896
Caspase-7Cricetulus griseus (Chinese hamster)Potency43.98710.006723.496068.5896AID1346980
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency5.80480.00419.984825.9290AID504444
caspase-3Cricetulus griseus (Chinese hamster)Potency43.98710.006723.496068.5896AID1346980
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency0.18240.000323.4451159.6830AID743065; AID743067
histone deacetylase 9 isoform 3Homo sapiens (human)Potency23.01320.037617.082361.1927AID1259364; AID1259388
heat shock protein beta-1Homo sapiens (human)Potency13.80060.042027.378961.6448AID743210
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency36.41320.000627.21521,122.0200AID743219
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency0.02000.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency0.02000.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency0.02000.15855.287912.5893AID540303
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency14.34840.00798.23321,122.0200AID2546; AID2551
gemininHomo sapiens (human)Potency1.19020.004611.374133.4983AID624296; AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency1.11940.005612.367736.1254AID624032; AID624044
lamin isoform A-delta10Homo sapiens (human)Potency2.66400.891312.067628.1838AID1487
Rap guanine nucleotide exchange factor 3Homo sapiens (human)Potency3.16236.309660.2008112.2020AID720709
Interferon betaHomo sapiens (human)Potency1.29530.00339.158239.8107AID1347407; AID1347411
Cellular tumor antigen p53Homo sapiens (human)Potency0.11390.002319.595674.0614AID651631; AID720552
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency9.58900.011917.942071.5630AID651632; AID720516
Ataxin-2Homo sapiens (human)Potency8.11370.011912.222168.7989AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Methionine aminopeptidaseEscherichia coli K-12IC50 (µMol)10.00000.47203.50775.0000AID259066
Fatty-acid amide hydrolase 1Rattus norvegicus (Norway rat)IC50 (µMol)10.00000.00051.33138.0000AID259066
Mitogen-activated protein kinase 14Homo sapiens (human)IC50 (µMol)3.18800.00010.72667.8000AID625182
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Nuclear receptor subfamily 1 group I member 2Homo sapiens (human)EC50 (µMol)10.00000.00203.519610.0000AID1215086
Nuclear receptor subfamily 1 group I member 2Rattus norvegicus (Norway rat)EC50 (µMol)4.00000.01004.139410.0000AID1215090
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (249)

Processvia Protein(s)Taxonomy
negative regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic metabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
signal transductionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
steroid metabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of gene expressionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic catabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic transportNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear receptor subfamily 1 group I member 2Homo sapiens (human)
cell differentiationNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor subfamily 1 group I member 2Homo sapiens (human)
angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 3Homo sapiens (human)
signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 3Homo sapiens (human)
associative learningRap guanine nucleotide exchange factor 3Homo sapiens (human)
Rap protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of actin cytoskeleton organizationRap guanine nucleotide exchange factor 3Homo sapiens (human)
negative regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
intracellular signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of GTPase activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of protein export from nucleusRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of stress fiber assemblyRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
establishment of endothelial barrierRap guanine nucleotide exchange factor 3Homo sapiens (human)
cellular response to cAMPRap guanine nucleotide exchange factor 3Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 3Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
proteolysisMethionine aminopeptidaseEscherichia coli K-12
positive regulation of blood vessel endothelial cell migrationMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to lipopolysaccharideMitogen-activated protein kinase 14Homo sapiens (human)
DNA damage checkpoint signalingMitogen-activated protein kinase 14Homo sapiens (human)
cell morphogenesisMitogen-activated protein kinase 14Homo sapiens (human)
cartilage condensationMitogen-activated protein kinase 14Homo sapiens (human)
angiogenesisMitogen-activated protein kinase 14Homo sapiens (human)
osteoblast differentiationMitogen-activated protein kinase 14Homo sapiens (human)
placenta developmentMitogen-activated protein kinase 14Homo sapiens (human)
response to dietary excessMitogen-activated protein kinase 14Homo sapiens (human)
chondrocyte differentiationMitogen-activated protein kinase 14Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusMitogen-activated protein kinase 14Homo sapiens (human)
glucose metabolic processMitogen-activated protein kinase 14Homo sapiens (human)
regulation of transcription by RNA polymerase IIMitogen-activated protein kinase 14Homo sapiens (human)
transcription by RNA polymerase IIMitogen-activated protein kinase 14Homo sapiens (human)
apoptotic processMitogen-activated protein kinase 14Homo sapiens (human)
chemotaxisMitogen-activated protein kinase 14Homo sapiens (human)
signal transductionMitogen-activated protein kinase 14Homo sapiens (human)
cell surface receptor signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
cell surface receptor protein serine/threonine kinase signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
skeletal muscle tissue developmentMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of gene expressionMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of myotube differentiationMitogen-activated protein kinase 14Homo sapiens (human)
peptidyl-serine phosphorylationMitogen-activated protein kinase 14Homo sapiens (human)
fatty acid oxidationMitogen-activated protein kinase 14Homo sapiens (human)
platelet activationMitogen-activated protein kinase 14Homo sapiens (human)
regulation of ossificationMitogen-activated protein kinase 14Homo sapiens (human)
osteoclast differentiationMitogen-activated protein kinase 14Homo sapiens (human)
stress-activated protein kinase signaling cascadeMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of cyclase activityMitogen-activated protein kinase 14Homo sapiens (human)
lipopolysaccharide-mediated signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
response to muramyl dipeptideMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of interleukin-12 productionMitogen-activated protein kinase 14Homo sapiens (human)
response to insulinMitogen-activated protein kinase 14Homo sapiens (human)
negative regulation of hippo signalingMitogen-activated protein kinase 14Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusMitogen-activated protein kinase 14Homo sapiens (human)
response to muscle stretchMitogen-activated protein kinase 14Homo sapiens (human)
p38MAPK cascadeMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of protein import into nucleusMitogen-activated protein kinase 14Homo sapiens (human)
signal transduction in response to DNA damageMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of erythrocyte differentiationMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of myoblast differentiationMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIMitogen-activated protein kinase 14Homo sapiens (human)
glucose importMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of glucose importMitogen-activated protein kinase 14Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
stem cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
striated muscle cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of muscle cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
stress-activated MAPK cascadeMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of cardiac muscle cell proliferationMitogen-activated protein kinase 14Homo sapiens (human)
bone developmentMitogen-activated protein kinase 14Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to lipoteichoic acidMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to tumor necrosis factorMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to ionizing radiationMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to UV-BMitogen-activated protein kinase 14Homo sapiens (human)
negative regulation of canonical Wnt signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of brown fat cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
cellular senescenceMitogen-activated protein kinase 14Homo sapiens (human)
stress-induced premature senescenceMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to virusMitogen-activated protein kinase 14Homo sapiens (human)
regulation of synaptic membrane adhesionMitogen-activated protein kinase 14Homo sapiens (human)
regulation of cytokine production involved in inflammatory responseMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of myoblast fusionMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processMitogen-activated protein kinase 14Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (64)

Processvia Protein(s)Taxonomy
RNA polymerase II transcription regulatory region sequence-specific DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear receptor activityNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
protein bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
zinc ion bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear receptor bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein domain specific bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
aminopeptidase activityMethionine aminopeptidaseEscherichia coli K-12
initiator methionyl aminopeptidase activityMethionine aminopeptidaseEscherichia coli K-12
ferrous iron bindingMethionine aminopeptidaseEscherichia coli K-12
metalloexopeptidase activityMethionine aminopeptidaseEscherichia coli K-12
metal ion bindingMethionine aminopeptidaseEscherichia coli K-12
metalloaminopeptidase activityMethionine aminopeptidaseEscherichia coli K-12
protein serine/threonine kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
MAP kinase kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
protein bindingMitogen-activated protein kinase 14Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 14Homo sapiens (human)
enzyme bindingMitogen-activated protein kinase 14Homo sapiens (human)
protein phosphatase bindingMitogen-activated protein kinase 14Homo sapiens (human)
mitogen-activated protein kinase p38 bindingMitogen-activated protein kinase 14Homo sapiens (human)
NFAT protein bindingMitogen-activated protein kinase 14Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (41)

Processvia Protein(s)Taxonomy
nucleoplasmNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
transcription regulator complexNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear bodyNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
intermediate filament cytoskeletonNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
chromatinNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nucleusNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
cortical actin cytoskeletonRap guanine nucleotide exchange factor 3Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
microvillusRap guanine nucleotide exchange factor 3Homo sapiens (human)
endomembrane systemRap guanine nucleotide exchange factor 3Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
lamellipodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
filopodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
extracellular exosomeRap guanine nucleotide exchange factor 3Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
cytosolMethionine aminopeptidaseEscherichia coli K-12
cytosolMethionine aminopeptidaseEscherichia coli K-12
cytosolMitogen-activated protein kinase 14Homo sapiens (human)
spindle poleMitogen-activated protein kinase 14Homo sapiens (human)
extracellular regionMitogen-activated protein kinase 14Homo sapiens (human)
nucleusMitogen-activated protein kinase 14Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 14Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 14Homo sapiens (human)
mitochondrionMitogen-activated protein kinase 14Homo sapiens (human)
cytosolMitogen-activated protein kinase 14Homo sapiens (human)
nuclear speckMitogen-activated protein kinase 14Homo sapiens (human)
secretory granule lumenMitogen-activated protein kinase 14Homo sapiens (human)
glutamatergic synapseMitogen-activated protein kinase 14Homo sapiens (human)
ficolin-1-rich granule lumenMitogen-activated protein kinase 14Homo sapiens (human)
nucleusMitogen-activated protein kinase 14Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 14Homo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (125)

Assay IDTitleYearJournalArticle
AID1645848NCATS Kinetic Aqueous Solubility Profiling2019Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347138qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D caspase screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508612NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Highly predictive and interpretable models for PAMPA permeability.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347136qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347140qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347139qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347141qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347137qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for Daoy cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347135qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID320675Tmax in pig at 5.0 mg/kg, po assessed as fenbendazole sulfoxide level2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Highly water-soluble prodrugs of anthelmintic benzimidazole carbamates: synthesis, pharmacodynamics, and pharmacokinetics.
AID320670AUC in pig at 5.0 mg/kg, po2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Highly water-soluble prodrugs of anthelmintic benzimidazole carbamates: synthesis, pharmacodynamics, and pharmacokinetics.
AID658935Aqueous solubility of the compound2012European journal of medicinal chemistry, Jun, Volume: 52Exploring the interplay of physicochemical properties, membrane permeability and giardicidal activity of some benzimidazole derivatives.
AID320668Tmax in pig at 5.0 mg/kg, po2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Highly water-soluble prodrugs of anthelmintic benzimidazole carbamates: synthesis, pharmacodynamics, and pharmacokinetics.
AID1403128Cytotoxicity against human PC3MLN4 cells assessed as reduction in cell viability after 48 hrs by cyquant reagent based fluorescence spectrometric assay2018European journal of medicinal chemistry, Jan-20, Volume: 144Synthesis and anticancer activity of novel water soluble benzimidazole carbamates.
AID320684Anthelmintic activity against Oesophagostomum dentatum infected pig assessed as worm burden reduction2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Highly water-soluble prodrugs of anthelmintic benzimidazole carbamates: synthesis, pharmacodynamics, and pharmacokinetics.
AID320676AUC in pig at 5.0 mg/kg, po assessed as fenbendazole sulfoxide level2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Highly water-soluble prodrugs of anthelmintic benzimidazole carbamates: synthesis, pharmacodynamics, and pharmacokinetics.
AID1215092Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 up to 46 uM after 24 hrs by luminescent analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID1215086Activation of human PXR expressed in human HepG2 (DPX-2) cells after 24 hrs by luciferase reporter gene based luminescent analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID320666Cmax in pig at 5.0 mg/kg, po2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Highly water-soluble prodrugs of anthelmintic benzimidazole carbamates: synthesis, pharmacodynamics, and pharmacokinetics.
AID358923Anthelmintic activity against Nippostrongylus brasiliensis2001Journal of natural products, Dec, Volume: 64, Issue:12
New sesquiterpene derivatives from the red alga Laurencia scoparia. Isolation, structure determination, and anthelmintic activity.
AID1403129Cytotoxicity against human PC3M cells assessed as reduction in cell viability after 48 hrs by cyquant reagent based fluorescence spectrometric assay2018European journal of medicinal chemistry, Jan-20, Volume: 144Synthesis and anticancer activity of novel water soluble benzimidazole carbamates.
AID117711Compound (62.5 p.p.m.) was tested for percent reduction of Nematospiroides dubius in mice1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Isomeric phenylthioimidazo[1,2-alpha]pyridines as anthelmintics.
AID1215097Activation of rat PXR expressed in human HepG2 cells after 24 hrs by luciferase reporter gene based luminescent analysis relative to dexamethasone2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID320682AUC in pig at 5.0 mg/kg, po assessed as fenbendazole sulfone level2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Highly water-soluble prodrugs of anthelmintic benzimidazole carbamates: synthesis, pharmacodynamics, and pharmacokinetics.
AID320681Tmax in pig at 5.0 mg/kg, po assessed as fenbendazole sulfone level2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Highly water-soluble prodrugs of anthelmintic benzimidazole carbamates: synthesis, pharmacodynamics, and pharmacokinetics.
AID1215090Activation of rat PXR expressed in human HepG2 cells after 24 hrs by luciferase reporter gene based luminescent analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID259066Inhibition of Co2+ loaded MetAP expressed in Escherichia coli2006Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2
Metal-mediated inhibition of Escherichia coli methionine aminopeptidase: structure-activity relationships and development of a novel scoring function for metal-ligand interactions.
AID519608Selectivity index, ratio of TC50 for hepatocytes to IC50 for Plasmodium yoelii 2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
New active drugs against liver stages of Plasmodium predicted by molecular topology.
AID1215096Activation of human PXR expressed in human HepG2 (DPX-2) cells after 24 hrs by luciferase reporter gene based luminescent analysis relative to rifampicin2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID658934Lipophilicity, logkw of the compound by RP-HPLC analysis2012European journal of medicinal chemistry, Jun, Volume: 52Exploring the interplay of physicochemical properties, membrane permeability and giardicidal activity of some benzimidazole derivatives.
AID117710Compound (500 p.p.m.) was tested for percent reduction of Nematospiroides dubius in mice1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Isomeric phenylthioimidazo[1,2-alpha]pyridines as anthelmintics.
AID489471Inhibition of Staphylococcus aureus MetAP at 25 uM2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
Subtype-selectivity of metal-dependent methionine aminopeptidase inhibitors.
AID259067Inhibition of Mn2+ loaded MetAP expressed in Escherichia coli at upto 10 uM2006Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2
Metal-mediated inhibition of Escherichia coli methionine aminopeptidase: structure-activity relationships and development of a novel scoring function for metal-ligand interactions.
AID489469Inhibition of Escherichia coli MetAP at 25 uM2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
Subtype-selectivity of metal-dependent methionine aminopeptidase inhibitors.
AID117708Compound (125 p.p.m.) was tested for percent reduction of Nematospiroides dubius in mice1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Isomeric phenylthioimidazo[1,2-alpha]pyridines as anthelmintics.
AID320674Cmax in pig at 5.0 mg/kg, po assessed as fenbendazole sulfoxide level2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Highly water-soluble prodrugs of anthelmintic benzimidazole carbamates: synthesis, pharmacodynamics, and pharmacokinetics.
AID489473Inhibition of human MetAP1 at 25 uM2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
Subtype-selectivity of metal-dependent methionine aminopeptidase inhibitors.
AID320680Cmax in pig at 5.0 mg/kg, po assessed as fenbendazole sulfone level2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Highly water-soluble prodrugs of anthelmintic benzimidazole carbamates: synthesis, pharmacodynamics, and pharmacokinetics.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID117709Compound (250 p.p.m.) was tested for percent reduction of Nematospiroides dubius in mice1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Isomeric phenylthioimidazo[1,2-alpha]pyridines as anthelmintics.
AID658931Antiparasitic activity against Giardia duodenalis IMSS:0989 after 48 hrs2012European journal of medicinal chemistry, Jun, Volume: 52Exploring the interplay of physicochemical properties, membrane permeability and giardicidal activity of some benzimidazole derivatives.
AID658936Distribution coefficient, log D of the compound2012European journal of medicinal chemistry, Jun, Volume: 52Exploring the interplay of physicochemical properties, membrane permeability and giardicidal activity of some benzimidazole derivatives.
AID519607Cytotoxicity against Hepatocyte cells assessed as cell viability by MTT assay2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
New active drugs against liver stages of Plasmodium predicted by molecular topology.
AID1403130Selectivity ratio of EC50 for cytotoxicity against human PC3M cells to EC50 for cytotoxicity against human PC3MLN4 cells2018European journal of medicinal chemistry, Jan-20, Volume: 144Synthesis and anticancer activity of novel water soluble benzimidazole carbamates.
AID320664Stability in presence of pig jejunum alkaline phosphatase assessed as prodrug conversion at pH 6.52008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Highly water-soluble prodrugs of anthelmintic benzimidazole carbamates: synthesis, pharmacodynamics, and pharmacokinetics.
AID320663Stability in presence of pig duodenum alkaline phosphatase assessed as prodrug conversion at pH 6.52008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Highly water-soluble prodrugs of anthelmintic benzimidazole carbamates: synthesis, pharmacodynamics, and pharmacokinetics.
AID489475Inhibition of human MetAP2 expressed in baculovirus infected Sf9 cells at 25 uM2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
Subtype-selectivity of metal-dependent methionine aminopeptidase inhibitors.
AID320683Anthelmintic activity against Oesophagostomum dentatum infected pig assessed as reduction in fecal egg shedding2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Highly water-soluble prodrugs of anthelmintic benzimidazole carbamates: synthesis, pharmacodynamics, and pharmacokinetics.
AID468443Inhibition of human FAAH at 1 uM2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Mining biologically-active molecules for inhibitors of fatty acid amide hydrolase (FAAH): identification of phenmedipham and amperozide as FAAH inhibitors.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID259068Inhibition of Co2+ loaded MetAP expressed in Escherichia coli at 10 uM2006Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2
Metal-mediated inhibition of Escherichia coli methionine aminopeptidase: structure-activity relationships and development of a novel scoring function for metal-ligand interactions.
AID519606Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
New active drugs against liver stages of Plasmodium predicted by molecular topology.
AID1215088Competitive binding affinity to human PXR LBD (111 to 434) up to 46 uM by TR-FRET assay2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1508591NCATS Rat Liver Microsome Stability Profiling2020Scientific reports, 11-26, Volume: 10, Issue:1
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (876)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990272 (31.05)18.7374
1990's182 (20.78)18.2507
2000's150 (17.12)29.6817
2010's171 (19.52)24.3611
2020's101 (11.53)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 60.07

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index60.07 (24.57)
Research Supply Index6.90 (2.92)
Research Growth Index4.63 (4.65)
Search Engine Demand Index206.77 (26.88)
Search Engine Supply Index3.99 (0.95)

This Compound (60.07)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials80 (8.73%)5.53%
Reviews17 (1.86%)6.00%
Case Studies70 (7.64%)4.05%
Observational0 (0.00%)0.25%
Other749 (81.77%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
"Safeguard Your Smile an Oral Health Literacy Intervention Promoting Positive Oral Hygiene Self-care Behavior Among Punjabi Immigrants: A Randomized Controlled Trial" [NCT02521155]140 participants (Actual)Interventional2015-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]